EPHB1: IHC Expression in Cancer and Radioligand Target Profile
EPHB1, EPH receptor B1, is a cell-surface protein (membrane receptor). In Human Protein Atlas immunohistochemistry, EPHB1 staining is highest in breast cancer (55% of samples positive), colorectal cancer (33% of samples positive) and thyroid cancer (33% of samples positive). Evidence on whether EPHB1 internalizes is mixed. Clinical status: FDA-approved drug (any modality).
Is EPHB1 the right target for your program? Rank it against 15,000 targets on dosimetry, internalization and clinical risk.
Analyze EPHB1 freeIs EPHB1 a good radioligand therapy target?
Scored against the six criteria that decide whether a protein can become a radioligand therapy:
- ✅ Cell-surface accessibility: Localized to the cell surface, so a radioligand can reach it from circulation.
- ⚠️ Tumor expression: Low IHC staining in breast cancer, 55% of samples positive.
- ⚠️ Internalization: Mixed evidence.
- ✅ Clinical precedent: FDA-approved drug (any modality)
- ❔ Shedding: Not yet assessed.
- ❔ Normal-tissue dosimetry: Check kidney, liver, bone marrow and salivary expression in the Human Protein Atlas tissue atlas.
EPHB1 IHC staining by cancer type
Protein expression of EPHB1 across 20 cancer types from Human Protein Atlas immunohistochemistry. The score is a weighted staining intensity from 0 to 1; "% positive" is the share of patient samples with detectable staining.
| Cancer type | IHC score | Level | % positive |
|---|---|---|---|
| Breast Cancer | 0.18 | Low | 55% |
| Colorectal Cancer | 0.11 | Low | 33% |
| Thyroid Cancer | 0.11 | Low | 33% |
| Melanoma | 0.09 | Low | 27% |
| Kidney Cancer | 0.09 | Low | 18% |
| Skin Cancer | 0.08 | Low | 25% |
| Testicular Cancer | 0.06 | Low | 17% |
| Ovarian Cancer | 0.06 | Low | 8% |
| Cervical Cancer | 0.03 | Low | 10% |
| Pancreatic Cancer | 0.03 | Low | 9% |
| Bladder Cancer | 0.03 | Low | 8% |
Not detected by IHC in: head and neck cancer, lymphoma, neuroendocrine tumors, lung cancer, prostate cancer, gastric cancer, endometrial cancer, glioma, liver cancer.
Is EPHB1 internalized?
Uncertain. While the abstract discusses ephrin ligands and their role in promoting receptor internalization and degradation, it does not explicitly state whether EphB1 itself undergoes internalization upon ligand binding. It mentions EphB1's enhanced angiogenesis and migratory capacity but lacks direct evidence regarding its internalization.
Sources: PMID 41200151 · PMID 25834064 · PMID 22579729 · PMID 15351694. AI-extracted from abstracts, so verify before citing.
EPHB1 clinical trials
FDA-approved drug (any modality). Nuclens hasn't indexed trials for EPHB1 yet. Search ClinicalTrials.gov for EPHB1 trials.
EPHB1 normal tissue expression
Normal-tissue expression in dose-limiting organs (kidney, liver, bone marrow, salivary glands) drives radioligand dosimetry risk. Nuclens is re-validating its normal-tissue values, so they are not shown here yet. See EPHB1 in the Human Protein Atlas tissue atlas, and read how normal-tissue expression predicts radioligand dosimetry risk.
EPHB1 gene essentiality (DepMap)
CRISPR knockout effect across 1255 cancer cell lines: 0.04 (not essential). Radioligands kill by radiation, not by blocking the target, so essentiality matters less than for inhibitors. A non-essential target can still be an excellent radioligand target.
Related breast cancer radioligand targets
HER3 (ERBB3) · c-MET (MET) · FAP · HER2 (ERBB2) · STEAP2 · EGFR · SSTR2 · B7-H3 (CD276)
See all radioligand therapy targets in breast cancer.
See how EPHB1 ranks against 15,000 targets for your indication.
Analyze EPHB1 freeData sources
Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.